Related Experiment Video

Updated: Jun 11, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Real-World Outcomes of Thromboprophylaxis With Apixaban in Patients With Newly Diagnosed Multiple Myeloma, the

K Alexandra Sanchez1, Gabriela Cesarman-Maus1, Michelle Flores-Cruz1

  • 1Department of Hematology Instituto Nacional de Cancerología Mexico City Mexico.

Ejhaem
|June 10, 2026
PubMed
Abstract

Insights

Apixaban is a safe and effective option for preventing blood clots in newly diagnosed multiple myeloma patients. This study found very low rates of thrombotic and bleeding events, supporting its use.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Multiple myeloma (MM) is associated with a high risk of venous thromboembolism (VTE).
  • Current thromboprophylaxis options like aspirin have limited efficacy.
  • Factor-Xa inhibitors show potential for VTE prevention in MM.

Purpose of the Study:

  • To evaluate the safety and efficacy of apixaban for primary thromboprophylaxis.
  • To assess apixaban's role in newly diagnosed multiple myeloma (NDMM) patients.

Main Methods:

  • Prospective, single-center study design.
  • Inclusion of consecutive patients receiving apixaban.
  • Monitoring for VTE and bleeding events.

Main Results:

  • Eighty-seven patients were included with a median follow-up of 11 months.
  • No major bleeding, deep vein thrombosis, or pulmonary embolism events were recorded.
  • Two patients experienced symptomatic superficial vein thrombosis.

Conclusions:

  • Apixaban demonstrated safety in NDMM patients.
  • Very low rates of clinically significant thrombotic and bleeding events were observed.
  • Further evaluation of apixaban for thromboprophylaxis in NDMM is warranted.
Keywords:
Anti‐Xa oral anticoagulantsmultiple myelomathromboprophylaxisthrombotic risk scoresvenous thromboembolism

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.